Article | Open | Published:

Comprehensive molecular characterization of urothelial bladder carcinoma

Nature volume 507, pages 315322 (20 March 2014) | Download Citation

This article has been updated


Urothelial carcinoma of the bladder is a common malignancy that causes approximately 150,000 deaths per year worldwide. So far, no molecularly targeted agents have been approved for treatment of the disease. As part of The Cancer Genome Atlas project, we report here an integrated analysis of 131 urothelial carcinomas to provide a comprehensive landscape of molecular alterations. There were statistically significant recurrent mutations in 32 genes, including multiple genes involved in cell-cycle regulation, chromatin regulation, and kinase signalling pathways, as well as 9 genes not previously reported as significantly mutated in any cancer. RNA sequencing revealed four expression subtypes, two of which (papillary-like and basal/squamous-like) were also evident in microRNA sequencing and protein data. Whole-genome and RNA sequencing identified recurrent in-frame activating FGFR3TACC3 fusions and expression or integration of several viruses (including HPV16) that are associated with gene inactivation. Our analyses identified potential therapeutic targets in 69% of the tumours, including 42% with targets in the phosphatidylinositol-3-OH kinase/AKT/mTOR pathway and 45% with targets (including ERBB2) in the RTK/MAPK pathway. Chromatin regulatory genes were more frequently mutated in urothelial carcinoma than in any other common cancer studied so far, indicating the future possibility of targeted therapy for chromatin abnormalities.


Urothelial carcinoma of the bladder is a major cause of morbidity and mortality worldwide, causing an estimated 150,000 deaths per year1. Previous studies have identified multiple regions of somatic copy number alteration, including amplification of PPARG, E2F3, EGFR, CCND1 and MDM2, as well as loss of CDKN2A and RB1 (refs 2, 3). Sequencing of candidate pathways has identified recurrent mutations in TP53, FGFR3, PIK3CA, TSC1, RB1 and HRAS (refs 2, 3). Whole-exome sequencing of nine bladder cancers, followed by a replication analysis of 88 cancers, identified mutations at >10% frequency in several chromatin remodelling genes: KDM6A, CREBBP, EP300 and ARID1A (ref. 4). Focused molecular analyses5,6 have delineated tumour subtypes and identified kinase-activating FGFR3 gene fusions7,8.

We report here a comprehensive, integrated study of 131 high-grade muscle-invasive urothelial bladder carcinomas as part of The Cancer Genome Atlas (TCGA) project. Included are data on DNA copy number, somatic mutation, messenger RNA and microRNA (miRNA) expression, protein and phosphorylated protein expression, DNA methylation, transcript splice variation, gene fusion, viral integration, pathway perturbation, clinical correlates and histopathology to characterize the molecular landscape of urothelial carcinoma. This study identifies a number of mutations and regions of copy number variation that involve genes not previously reported as altered in a significant fraction of bladder cancers. It also identifies potential therapeutic targets in most of the samples analysed.

Demographic, clinical and pathological data

Samples (from 19 tissue source sites) consisted of 131 chemotherapy-naive, muscle-invasive, high-grade urothelial tumours (T2-T4a, Nx, Mx), as well as peripheral blood (n = 118) and/or tumour-adjacent, histologically normal-appearing bladder tissue (n = 23). Cases were retained only if they met the following criteria: tumour nuclei constituted ≥60% of all nuclei; tumour necrosis was ≤20% of the specimen; and variant histologies (squamous or small cell) were ≤50% (Supplementary Information, section ‘Biospecimen collection and clinical data’). Clinical and demographic characteristics are described in Supplementary Data 1.1. Five expert genitourinary pathologists re-reviewed all of the cases for multiple parameters, including the extent of variant histology (Supplementary Fig. 1.1a and Supplementary Information, section ‘Biospecimen collection and clinical data’).

Somatic DNA alterations

The tumours displayed a large number of DNA alterations, slightly fewer than in lung cancer and melanoma, but more than in other adult malignancies studied by TCGA (Fig. 1)9. On average, there were 302 exonic mutations, 204 segmental alterations in genomic copy number and 22 genomic rearrangements per sample. We analysed somatic copy number alterations (CNAs) using both SNP 6.0 arrays and low-pass whole-genome sequencing; the two were strongly concordant (Supplementary Methods 6.1 and Supplementary Fig. 6.1). There were 22 significant arm-level copy number changes (Supplementary Data 6.1.1), and GISTIC (genomic identification of significant targets in cancer) (Supplementary Methods 6.2) identified 27 amplified and 30 deleted recurrent focal somatic CNAs (Supplementary Data 6.2.1 and 6.3.1). Focal amplifications involved genes previously reported to be altered in bladder cancer (Fig. 1c and Supplementary Fig. 6.2.1) and some not previously implicated. The latter included PVRL4, BCL2L1 and ZNF703. The most common recurrent focal deletion, seen in 47% of samples, contained CDKN2A (9p21.3) and correlated with reduced expression (Fig. 1 and Supplementary Fig. 2.7). Other focal deletions containing <10 genes appeared to target PDE4D, RB1, FHIT, CREBBP, IKZF2, FOXQ1, FAM190A (also called CCSER1), LRP1B and WWOX.

Figure 1: The genomic landscape of bladder cancer.
Figure 1

a, Mutation rate and type, histological subtype, smoking status, gender, tumour stage and cluster type. b, Genes with statistically significant levels of mutation (MutSig, false discovery rate <0.1) and mutation types. c, Deletions and amplifications for genomic regions with statistically significant focal copy number changes (GISTIC2.0). ‘Copy number’ refers to absolute copy number. Note that two amplification peaks (*) contain several genes, any of which could be the target, as opposed to the single gene listed here. d, RNA expression level for selected genes, expressed as fold change from the median value for all samples. Tumour samples were grouped into three clusters (red, blue and green) using consensus NMF clustering (see the main text and Supplementary Fig. 2.1.2). Three samples with no copy number data and two samples with no mutations in the genes were not used in the clustering and are shown in grey.

Whole-exome sequencing of 130 tumours and matched normal samples targeted 186,260 exons in 18,091 genes (mean coverage 100-fold, with 82% of target bases covered >30×). MuTect10 identified 39,312 somatic mutations (including 38,012 point mutations and 1,138 indels (insertions or deletions)), yielding mean and median somatic mutation rates of 7.7 and 5.5 per megabase (Mb), respectively (Fig. 1a and Supplementary Table 2.1.1). Thirty-two genes showed statistically significant levels of recurrent somatic mutation (Fig. 1b and Supplementary Table 2.1.2) by analysis using MutSig 1.5 (refs 9, 11) (Supplementary Methods 2.2). Three other genes identified by MutSig were not considered further because of low or undetectable expression (Supplementary Fig. 2.1.1). A similar analysis considering only mutations in the COSMIC database2 identified three more significantly mutated genes: ERBB2, ATM and CTNNB1 (Supplementary Table 2.1.3). We validated the mutation findings in three ways: targeted re-sequencing of all significantly mutated gene mutations, comparison with RNA-seq data for 123 samples and comparison with whole-genome sequence data for 18 samples. Overall, the validation rate was >99% in selected mutations by a combination of the methods (Supplementary Methods 2.4).

Nearly half (49%) of the samples had TP53 mutations (Fig. 1b), which were mutually exclusive in their relationship with amplification (9%) and overexpression (29%) of MDM2; hence, TP53 function was inactivated in 76% of samples. Most RB1 mutations were inactivating, were associated with significantly reduced mRNA level (Supplementary Fig. 2.7) and were mutually exclusive with CDKN2A deletions (Supplementary Fig. 2.8 and Supplementary Table 2.8.1). FGFR3 mutations (12%) typically affected known kinase-activating sites. PIK3CA mutations were relatively common (20%), clustering in the helical domain near E545 (Supplementary Fig. 2.4). Most TSC1 mutations (8%) were truncating, and six were homozygous (allele fraction >0.5).

Many of the 32 genes identified in Fig. 1b have not previously been reported as statistically significantly mutated in bladder cancer: MLL2 (also called KMT2D; 27%), CDKN1A* (14%), ERCC2* (12%), STAG2 (11%), RXRA* (9%), ELF3* (8%), NFE2L2 (8%), KLF5* (8%), TXNIP (7%), FOXQ1* (5%), RHOB* (5%), FOXA1 (5%), PAIP1* (5%), BTG2* (5%), ZFP36L1 (5%), RHOA (4%) and CCND3 (4%). The nine genes marked with asterisks have not been reported as significantly mutated genes in any other TCGA cancer type or reported in another study as mutated at >3% frequency2. CDKN1A (p21CIP1), a cyclin-dependent kinase inhibitor12, had predominantly null or truncating mutations, indicating loss of function. Fifteen of sixteen mutations in ERCC2, a nucleotide excision repair gene13, were deleterious missense mutations, suggesting dominant-negative effects. ERCC2-mutant tumours also had significantly fewer C>G mutations than did ERCC2-wild-type tumours (Supplementary Figs 2.3.1 and 2.3.2), and they trended towards higher overall mutation rate (Supplementary Fig. 2.12). Seven of twelve mutations in RXRA (retinoid X nuclear receptor alpha)14 occurred at the same amino acid (five S427F; two S427Y) in the ligand-binding domain. Those seven tumours showed increased expression of genes involved in adipogenesis and lipid metabolism (Supplementary Fig. 2.6 and Supplementary Data 2.6.1–2.6.3), suggesting that the mutations cause constitutive activation.

Eleven tumours (8%) had deleterious missense mutations in the Neh2 domain of NFE2L2, a transcription factor that regulates the anti-oxidant program in response to oxidative stress15. Those tumours showed markedly increased expression of genes involved in genotoxic metabolism and the reactive oxygen species (ROS) response (Supplementary Figs 2.5.1–2.5.3 and Supplementary Data 2.5.2). Furthermore, nine samples had mutations in redox regulator TXNIP (ref. 16) (five of them inactivating) and were mutually exclusive of samples with NFE2L2 mutations, providing another mechanism for dysregulation of redox metabolism. Predominant inactivating mutations were seen in STAG2, an X-linked cohesin complex component required for separation of sister chromatids during cell division17 (Supplementary Fig. 2.4).

Unsupervised clustering by non-negative matrix factorization of mutations and focal somatic CNAs in 125 samples identified three distinct groups (Fig. 1a and Supplementary Fig. 2.1.2). Group A (red), classified as ‘focally amplified’, is highly enriched in focal somatic CNAs in several genes, as well as mutations in MLL2 (Fig. 1 and Supplementary Tables 2.1.4 and 2.1.5). Group B (blue), classified as ‘papillary CDKN2A-deficient FGFR3 mutant’, is enriched in papillary histology. Nearly all group B samples show loss of CDKN2A, and most have one or more alterations in FGFR3. Group C (green), classified as ‘TP53/cell-cycle-mutant’, shows TP53 mutations in nearly all samples, as well as enrichment with RB1 mutations and amplifications of E2F3 and CCNE1 (Fig. 1 and Supplementary Table 2.1.4). These differences in pattern of mutation suggest the possibility of different oncogenic mechanisms.

Seventy-two per cent of the cancers in this study were from current or past smokers, consistent with extensive epidemiological studies indicating an association between smoking and urothelial cancer risk. In contrast with lung cancer, however, there was no statistically significant association between smoking status and the mutational spectrum, frequency of mutation in any significantly mutated gene, occurrence of focal somatic CNAs or expression subtype (Supplementary Tables 2.9.1 and 2.9.2). Never-smokers did have a slightly higher fraction of C>G mutations than did current/former smokers (28.5% versus 23.8%, P = 0.032; Supplementary Figs 2.3.2 and 2.3.3). Unsupervised clustering of promoter CpG island DNA methylation data revealed a major subgroup (34%) of tumours (CIMP) characterized by cancer-specific DNA hypermethylation (Supplementary Fig. 7.1). Multivariate regression analysis with age, sex and tumour stage as covariates identified smoking pack-years as the only significant predictor of CIMP phenotype, as has also been reported for colorectal cancer18.

Fifty-one per cent of mutations overall were Tp*C->(T/G) (Supplementary Table 2.1.1), a class of mutation recently reported to be mediated by one of the DNA cytosine deaminases, APOBEC (refs 19, 20). APOBEC3B was expressed at high levels in all of the tumours, suggesting a major role for APOBEC-mediated mutagenesis in bladder carcinogenesis (Supplementary Figs 12.1 and 12.2).

Four genes involved in epigenetic regulation were significantly mutated genes: MLL2, ARID1A, KDM6A and EP300 (Fig. 1). Truncating mutations were significantly enriched in each of those genes (Supplementary Fig. 2.2 and Supplementary Data 2.2.1–2). Three of the genes had previously been identified as mutated in urothelial cancers4, but mutation of MLL2, which encodes a histone H3 lysine 4 (H3K4) methyltransferase, is a novel finding. Several other chromatin-regulating genes had mutation rates ≥10% but were not statistically significant by MutSig analysis: MLL3, MLL, CREBBP, CHD7 and SRCAP. Many other epigenetic regulators were mutated at lower frequency but were also enriched with truncating mutations, indicating functional significance (Supplementary Fig. 2.2 and Supplementary Data 2.2.1 and 2.2.2). Non-silent mutations in chromatin regulatory genes overall were significantly enriched in bladder cancer in comparison with the entire exome, in contrast with all other epithelial cancers studied so far in the TCGA project (Supplementary Table 2.10). Mutations in MLL2 and KDM6A (the latter encoding a histone H3 lysine 27 (H3K27) demethylase) were mutually exclusive (Supplementary Fig. 2.8 and Supplementary Table 2.8.1), suggesting that mutations in the two genes have redundant downstream effects on carcinogenesis or that the combined loss is synthetically lethal.

Chromosomal rearrangements and viral integration

To identify structural variations and pathogen sequences, we used low-pass, paired-end, whole-genome sequencing (WGS; 6–8× coverage) of 114 tumours and RNA sequencing of all tumours. We detected 2,529 structural aberrations, including 1,153 that involve gene–gene fusions. Among the translocations, 379 were inter-chromosomal, 237 were intra-chromosomal, 274 were the result of inversions and 263 resulted from deletions (Supplementary Table 3.1). We found several recurrent translocations of probable pathogenic significance, including an intra-chromosomal translocation on chromosome 4 involving FGFR3 and TACC3 (n = 3). The breakpoints were in intron 16 (two cases) or exon 17 (one case) of FGFR3 and intron 10 of TACC3 (confirmed by DNA sequencing and RNA-seq). All three lead to fusion mRNA products for which the predicted proteins include the amino-terminal 758 amino acids of FGFR3 fused with the carboxy-terminal 191 amino acids of TACC3 (Fig. 2a). On the basis of the structure of the FGFR3–TACC3 fusion protein, we predict that it can auto-dimerize, leading to constitutive activation of the kinase domain of FGFR3. FGFR3–TACC3 fusion, which was recently described in both glioblastoma21 and bladder cancer7,8, represents a promising therapeutic target. The ERBB2 gene was also involved in translocations in four tumours, all with different fusion partners and all confirmed by DNA sequencing, RNA-seq or both. In one case, exons 4 to 29 of ERBB2 were fused to the promoter plus exon 1 of DIP2B, and the fusion product was amplified (Fig. 2b). Two other fusion products resulted in novel mRNA products, the biological significance of which is not known.

Figure 2: Structural rearrangements and viral integration.
Figure 2

a, FGFR3–TACC3 fusion in sample TCGA-CF-A3MH showing the breakpoints in the two genes, the breakpoint junction sequences and the predicted fusion protein. b, Rearrangement involving DIP2B and ERBB2 in TCGA-DK-A2I6. The ERBB2 gene has swapped its promoter with that of DIP2B, resulting in overexpression of ERBB2. c, Insertion of human papilloma virus 16 (HPV16) into the BCL2L1 gene on chromosome 20 in TCGA-GC-A3I6. The region of BCL2L1 into which the virus has integrated and the integration junction sequence are shown.

We identified viral DNAs in 7 of 122 tumours (6%), and viral transcripts in 5 of 122 (4%). Three tumours expressed cytomegalovirus (CMV) transcripts (encoding RL5A, RNA2.7, RL9A, RNA1.2, UL5 and UL22A), one expressed BK polyoma virus and one expressed human papilloma virus 16 (HPV16). HPV16 and human herpesvirus 6B DNA were each identified in one other sample but without expression. None of the tumours expressing CMV showed evidence of CMV integration into the host genome, suggesting the presence of a stable episome. In the BK-positive tumour, two BK genes were integrated into GRB14, a signalling adaptor protein for receptor tyrosine kinases. In the HPV-16-expressing case, the virus integrated into BCL2L1, an apoptosis-regulating gene (Fig. 2c). In that tumour, BCL2L1 was amplified (6×) and overexpressed (10× median; >2× any of the other samples). Overall, these findings indicate that viral infection may have a role in the development of a small percentage of urothelial carcinomas.

mRNA, miRNA and protein expression

Analysis of RNA-seq data from 129 tumours identified four clusters (clusters I–IV) (Fig. 3 and Supplementary Fig. 4.1). Cluster I (‘papillary-like’) is enriched in tumours with papillary morphology (P = 0.0002), FGFR3 mutations (P = 0.0007, q = 0.02), FGFR3 copy number gain (P = 0.04, q = 0.1) and elevated FGFR3 expression (P < 0.0001) (Fig. 3a). It includes all three samples with FGFR3–TACC3 fusions. Cluster I samples also show significantly lower expression of miR-99a and miR-100, miRNAs that downregulate FGFR3 expression (P = 0.0002, Figs 3a and Supplementary Fig. 5.3)22. Cluster I samples also show lower expression of miR-145 and miR-125b, which have been reported as frequently downregulated in bladder cancer23. Tumours with FGFR3 alterations, and perhaps other tumours that share the cluster I expression profile, may respond to inhibitors of FGFR or its downstream targets.

Figure 3: Expression characteristics of bladder cancer.
Figure 3

Integrated analysis of mRNA, miRNA and protein data led to identification of distinct subsets of urothelial carcinoma. Data for mRNA, miRNA and protein were z-normalized, and samples were organized in the horizontal direction by mRNA clustering. a, Papillary histology, FGFR3 alterations, FGFR3 expression and reduced FGFR3-related miRNA expression are enriched in cluster I. b, Expression of epithelial lineage genes and stem/progenitor cytokeratins are generally high in cluster III, some of which show variant squamous histology. c, Luminal breast and urothelial differentiation factors are enriched in clusters I and II. d, ERBB2 mutation and oestrogen receptor beta (ESR2) expression are enriched in clusters I and II.

Reverse-phase protein array (RPPA) data indicate that clusters I and II express high HER2 (ERBB2) levels and an elevated oestrogen receptor beta (ESR2) signalling signature, indicating potential targets for hormone therapies such as tamoxifen or raloxifene (Fig. 3d). In fact, HER2 protein levels in a subset of the tumours are comparable to those found in TCGA HER2-positive breast cancers23.

For comparison, we asked whether any of the four clusters show gene signatures similar to those identified in any other tumour type(s) among the first 11 analysed by TCGA. We found that the signature of bladder cancer cluster III (‘basal/squamous-like’) is similar to that of basal-like breast cancers, as well as squamous cell cancers of the head and neck and lung (Supplementary Fig. 4.2)24,25. All four of those cancer types express characteristic epithelial lineage genes, including KRT14, KRT5, KRT6A and EGFR. Basal-like subtype26 and squamous cell subtype27 of urothelial carcinoma have been independently reported. Many of the samples in bladder cluster III express cytokeratins (that is, KRT14 and KRT5) that were recently reported to mark stem/progenitor cells26. Some of those samples also show a level of variant squamous histology (Fig. 3b). Bladder clusters I and II show features similar to those of luminal A breast cancer, with high mRNA and protein expression of luminal breast differentiation markers, including GATA3 and FOXA1 (Fig. 3c). Markers of urothelial differentiation such as the uroplakins (for example, UPK3A) are also highly expressed in clusters I and II, as are the epithelial marker E-cadherin and members of the miR-200 family of miRNAs (which target multiple regulators of epithelial–mesenchymal transition)28 (Fig. 3c). Taken together, these observations indicate that, despite their diverse tissue origins, some bladder, breast, head and neck and lung cancers share common pathways of tumour development.

To determine whether the expression-based clusters could be seen in other data sets, we used the muscle-invasive bladder cancer samples from ref. 27, hierarchically clustering them with the genes used in our analysis. From the sample dendrogram, we identified four groups (Supplementary Fig. 4.3a). The four groups identified in the data set of ref. 27 correlated well with the four clusters identified in our TCGA data (Supplementary Fig. 4.3b).

When we analysed the RNA-seq data for transcript splice variation using SpliceSeq29 (Supplementary Information, section 11), one finding of interest was an average of 3% PKM1 and 97% PKM2 transcripts in the tumour samples. The PKM2 isoform of pyruvate kinase is the principal driver of a shift to aerobic glycolysis in tumours (the Warburg effect)30. Therefore, urothelial bladder cancers (and other cancer types) may prove sensitive to inhibition of glycolysis or related metabolic pathways.

Pathway analysis and therapeutic targeting

Integrated analysis of the mutation and copy-number data revealed three main pathways as frequently dysregulated in bladder cancer: cell cycle regulation (altered in 93% of cases); kinase and phosphatidylinositol-3-OH kinase (PI(3)K) signalling (72%); and chromatin remodelling, including mutations/somatic CNAs in histone-modifying genes (89%) and components of the SWI/SNF nucleosome remodelling complex (64%) (Fig. 4a). To complement these results for well-defined pathways, we applied network analysis methods to examine other possible interactions between genes and pathways (Fig. 4b). In particular, we used the TieDIE algorithm to search for causal regulatory interactions within the PARADIGM network, which connects mutated genes to active transcriptional hubs31,32. The analysis identified a sub-network linking mutated histone-modifying genes to a large array of activated transcription factors, indicating potential far-reaching effects of histone modification on other pathways (Supplementary Fig. 8.2.1) converging on MYC/MAX regulation. Both MYC and MAX showed similar levels of pathway activity, independent of mutations in chromatin genes, suggesting that mutations in histone-modifying genes provide just one mechanism for disruption of the MYC/MAX hub. By contrast, tumours with chromatin-related mutations showed differential activity of transcription factors FOXA2 and SP1, implicating de-differentiation processes as a result of the mutations. Our network analysis also identified HSP90AA1 as a critical signalling hub, indicating that inhibitors of HSP90 may have therapeutic value in urothelial carcinoma. Although the linkages between mutations and transcriptional changes were statistically significant in terms of their proximity in the network (as determined by permutation tests; see Supplementary Fig. 8.2), further studies will be needed to assess the biological relevance of the findings.

Figure 4: Altered pathways and networks in bladder cancer.
Figure 4

a, Somatic mutations and copy number alterations (CNA) in components of the p53/Rb pathway, RTK/RAS/PI(3)K pathway, histone modification system and SWI/SNF complex. Red, activating genetic alterations; blue, inactivating genetic alterations. Percentages shown denote activation or inactivation of at least one allele. b, The network connecting mutated histone-modifying genes to transcription factors with differential activity (methodology and larger implicated network in Supplementary Fig. 8.2.1). Each gene is depicted as a multi-ring circle with various levels of data, plotted such that each ‘spoke’ in the ring represents a single patient sample (same sample ordering for all genes). ‘PARADIGM’ ring, bioinformatically inferred levels of gene activity (red, higher activity); ‘Transcriptional activity’, mean mRNA levels of all of the targets of each transcription factor; ‘expression’, mRNA levels relative to normal (red, high); ‘Mutation in gene’, somatic mutation; ‘Mutation in histone modifier genes’, somatic mutation in at least one such gene; ‘IPL anti-correlation’, genes with PARADIGM integrated pathway levels (IPLs) inversely correlated with histone-gene mutation status. Gene–gene relationships are inferred using public resources.

Integrated analysis also identified mutations, copy number alterations or RNA expression changes affecting the PI(3)K/AKT/mTOR pathway in 42% of the tumours (Fig. 5a). Included were activating point mutations in PIK3CA (17%; potentially responsive to PI(3)K inhibitors), mutation or deletion of TSC1 or TSC2 (9%; potentially responsive to mTOR inhibitors) and overexpression of AKT3 (10%; potentially responsive to AKT inhibitors). We also observed mutations, genomic amplifications or gene fusions that affect the RTK/RAS pathway in 44% of the tumours (Fig. 5b, c). Included were events that can activate FGFR3 (17%; potentially responsive to FGFR inhibitors or antibodies), amplification of EGFR (9%; potentially responsive to EGFR antibodies or inhibitors), mutations of ERBB3 (6%; potentially sensitive to ERBB kinase inhibitors) and mutation or amplification of ERBB2 (9%; potentially sensitive to ERBB2 kinase inhibitors or antibodies). ERBB3 mutations in bladder cancer have been noted previously4, but statistically significant mutation of ERBB2 in bladder cancer has not been reported. Both genes are potential therapeutic targets in other diseases33,34,35. Notably, ERBB2 alterations were approximately as frequent in this study as in TCGA breast cancers, but with fewer amplifications and more mutations (Fig. 5d)24.

Figure 5: Potential targets in bladder cancer.
Figure 5

a, Alterations in the PI(3)K/AKT/mTOR pathway are mutually exclusive. Tumour samples are shown in columns; genes in rows. Only samples with at least one alteration are shown. AKT3 shows elevated expression in 10% of samples, independent of copy number (right panel). Hetloss, heterozygous loss. b, Receptor tyrosine kinases are altered, by any of several different mechanisms (amplification, mutation or fusion), in 45% of samples. Only mutations that are recurrent in this data set or previously reported in COSMIC are shown. c, Recurrent mutations in ERBB2 and ERBB3. The mutations shown in black are either recurrent in the TCGA data set or reported in COSMIC. Green, receptor L domain; red, furin-like cysteine-rich region; blue, growth factor receptor domain IV; yellow, tyrosine kinase domain. d, ERBB2 amplifications and recurrent mutations in other cancers profiled by TCGA. Missense mutations were counted in the following positions: G309, S310, L313, R678, T733, L755, V777, D769, V842, T862, R896 and M916I. In-frame insertions were counted between amino acids 774 and 776. Only tumour types with an alteration frequency ≥2% are shown.


This integrated study of 131 invasive urothelial bladder carcinomas provides numerous novel insights into disease biology and delineates multiple potential opportunities for therapeutic intervention. Treatment for muscle-invasive bladder cancer has not advanced beyond cisplatin-based combination chemotherapy and surgery in the past 30 years36, and no new drugs for the disease have been approved in that time. Median survival for patients with recurrent or metastatic bladder cancer remains 14–15 months with cisplatin-based chemotherapy, and there is no widely recognized second-line therapy37. With the exception of a single case report, there is also no known benefit from treatment with newer, targeted agents38. Several of the genomic alterations identified in this study, particularly those involving the PI(3)K/AKT/mTOR, CDKN2A/CDK4/CCND1 and RTK/RAS pathways, including ERBB2 (Her-2), ERBB3 and FGFR3, are amenable in principle to therapeutic targeting. Clinical trials based on patients with relevant druggable genomic alterations are warranted.

FGFR3 mutation is a common feature of low-grade non-invasive papillary urothelial bladder cancer, but it occurs at a much lower frequency in high-grade invasive bladder cancer. The cluster analysis in Fig. 3 highlights multiple mechanisms of FGFR3 activation, and its strong association with papillary morphology. The data presented here suggest a subset of muscle-invasive cancers that can potentially be targeted through FGFR3. Similarly, ERBB2 amplification may be targetable by strategies used in breast cancer, by small-molecule tyrosine kinase inhibitors or by novel immunotherapeutic approaches (NCT01353222)34. The data here provide further support for several on-going ERBB2-targeted trials in bladder cancer and further define the subpopulation of cancers suited to that approach. Finally, cluster III of the integrated expression profiling analysis reveals the existence of a urothelial carcinoma subtype with cancer stem-cell expression features (including KRT14 and KRT5), perhaps providing another avenue for therapeutic targeting.

The alterations identified in epigenetic pathways also suggest new possibilities for bladder cancer treatment. Ninety-nine (76%) of the tumours analysed here had an inactivating mutation in one or more of the chromatin regulatory genes, and 53 (41%) had at least two such mutations. Overall, the bladder cancers showed a mutational spectrum highly enriched with mutations in chromatin regulatory genes (Supplementary Table 2.10). Furthermore, integrated network analyses revealed a profound impact of those mutations on the activity levels of various transcription factors and pathways implicated in cancer. Drugs that target chromatin modifications—for example, recently developed agents that bind acetyl-lysine binding motifs (bromodomains)—might prove useful for treatment of the subset of bladder tumours that exhibit abnormalities in chromatin-modifying enzymes39. Our findings overall indicate bladder cancer as a prime candidate for exploration of that approach to therapy.

Methods Summary

Tumour and normal samples were obtained with institutional-review-board-approved consent and processed using a modified AllPrep kit (Qiagen) to obtain purified DNA and RNA. Quality-control analyses revealed only modest batch effects (Supplementary Information, section ‘Batch effects’). The tumours were profiled using Affymetrix SNP 6.0 microarrays for somatic CNAs, low-pass WGS (HiSeq) for somatic CNAs and translocations, RNA-seq (HiSeq) for mRNA and miRNA expression, Illumina Infinium (HumanMethylation450) arrays for DNA methylation, HiSeq for exome sequencing and RPPA for protein expression and phosphorylation. Statistical analysis and biological interpretation of the data were spearheaded by the TCGA genome data analysis centres. Sequence files are in CGHub ( All other molecular, clinical and pathological data are available through the TCGA Data Portal ( The data can be explored through a compendium of next-generation clustered heat maps (, the cBio Cancer Genomics Portal (, TieDIE (, SpliceSeq (, MBatch batch effects assessor ( and Regulome Explorer ( Also see Supplementary Information.

Change history

  • 19 March 2014

    Sequences in figure 2a were incorrect and have been fixed.


  1. 1.

    et al. Global cancer statistics. CA Cancer J. Clin. 61, 69–90 (2011)

  2. 2.

    et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39, D945–D950 (2011)

  3. 3.

    & Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. Urol. Oncol. 28, 409–428 (2010)

  4. 4.

    et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nature Genet. 43, 875–878 (2011)

  5. 5.

    , , & Novel tumor subgroups of urothelial carcinoma of the bladder defined by integrated genomic analysis. Clin. Cancer Res. 18, 5865–5877 (2012)

  6. 6.

    et al. Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. PLoS ONE 7, e38863 (2012)

  7. 7.

    , & Oncogenic FGFR3 gene fusions in bladder cancer. Hum. Mol. Genet. 22, 795–803 (2013)

  8. 8.

    et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 3, 636–647 (2013)

  9. 9.

    et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214–218 (2013)

  10. 10.

    et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nature Biotechnol. 31, 213–219 (2013)

  11. 11.

    et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495–501 (2014)

  12. 12.

    & p21WAF1 and tumourigenesis: 20 years after. Curr. Opin. Oncol. 25, 52–58 (2013)

  13. 13.

    The xeroderma pigmentosum group D (XPD) gene: one gene, two functions, three diseases. Genes Dev. 15, 15–23 (2001)

  14. 14.

    et al. Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPARγ and RXRα. Nucleic Acids Res. 22, 5628–5634 (1994)

  15. 15.

    et al. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc. Natl Acad. Sci. USA 105, 13568–13573 (2008)

  16. 16.

    , & TXNIP (VDUP-1, TBP-2): a major redox regulator commonly suppressed in cancer by epigenetic mechanisms. Int. J. Biochem. Cell Biol. 43, 1668–1673 (2011)

  17. 17.

    et al. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science 333, 1039–1043 (2011)

  18. 18.

    et al. Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J. Natl. Cancer Inst. 98, 1731–1738 (2006)

  19. 19.

    et al. Mutational processes molding the genomes of 21 breast cancers. Cell 149, 979–993 (2012)

  20. 20.

    et al. Clustered mutations in yeast and in human cancers can arise from damaged long single-strand DNA regions. Mol. Cell 46, 424–435 (2012)

  21. 21.

    et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 337, 1231–1235 (2012)

  22. 22.

    et al. MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways. Oncogene 30, 3489–3501 (2011)

  23. 23.

    et al. Aberrant expression of microRNAs in bladder cancer. Nature Rev. Urol. 10, 396–404 (2013)

  24. 24.

    Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61–70 (2012)

  25. 25.

    Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519–525 (2012)

  26. 26.

    , & Normal and neoplastic urothelial stem cells: getting to the root of the problem. Nature Rev. Urol. 9, 583–594 (2012)

  27. 27.

    et al. A molecular taxonomy for urothelial carcinoma. Clin. Cancer Res. 18, 3377–3386 (2012)

  28. 28.

    , , & The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J. Biol. Chem. 283, 14910–14914 (2008)

  29. 29.

    , , , & SpliceSeq: a resource for analysis and visualization of RNA-Seq data on alternative splicing and its functional impacts. Bioinformatics 28, 2385–2387 (2012)

  30. 30.

    et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452, 230–233 (2008)

  31. 31.

    et al. Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics 26, i237–i245 (2010)

  32. 32.

    Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43–49 (2013)

  33. 33.

    et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 3, 224–237 (2013)

  34. 34.

    et al. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc. Natl Acad. Sci. USA 109, 14476–14481 (2012)

  35. 35.

    et al. Oncogenic ERBB3 mutations in human cancers. Cancer Cell 23, 603–617 (2013)

  36. 36.

    National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer. Vol. 1.2012 (2012)

  37. 37.

    et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. 23, 4602–4608 (2005)

  38. 38.

    et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 338, 221 (2012)

  39. 39.

    et al. Selective inhibition of BET bromodomains. Nature 468, 1067–1073 (2010)

Download references


We are grateful to all of the patients and families who contributed to this study, as well as C. Gunter and L. Chastain for scientific editing and M. Sheth, J. Zhang and C. Ron Bouchard for administrative support. This work was supported by the following grants from the United States National Institutes of Health: U54 HG003273, U54 HG003067, U54 HG003079, U24 CA143799, U24 CA143835, U24 CA143840, U24 CA143843, U24 CA143845, U24 CA143848, U24 CA143858, U24 CA143866, U24 CA143867, U24 CA143882, U24 CA143883, U24 CA144025 and P01 CA120964. Additional personnel and funding sources are acknowledged in the Supplementary Information.

Author information


  1. Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

    • John N. Weinstein
    • , Rehan Akbani
    • , Bradley M. Broom
    • , Wenyi Wang
    • , Roeland G. W. Verhaak
    • , Wenbin Liu
    • , Zhenlin Ju
    • , Thomas Motter
    • , Bo Peng
    • , Michael Ryan
    • , Xiaoping Su
    • , Ji-Yeon Yang
    • , Philip L. Lorenzi
    • , Hui Yao
    • , Nianxiang Zhang
    •  & Jiexin Zhang
  2. Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

    • John N. Weinstein
    • , Wenbin Liu
    • , Zhenlin Ju
    • , Ji-Yeon Yang
    •  & Gordon B. Mills
  3. The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

    • David McConkey
    •  & Kenna R. Mills Shaw
  4. Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA.

    • Seth Lerner
    • , Weiguo Jian
    •  & Sebrina Tello
  5. Texas Cancer Research Biobank (TCRB), Baylor College of Medicine, Houston, Texas 77030, USA.

    • Seth Lerner
    • , Margaret Morgan
    • , Weiguo Jian
    • , Sebrina Tello
    • , Michael Ittman
    • , Patricia Castro
    • , Whitney D. McClenden
    •  & Richard Gibbs
  6. Human Genome Sequencing Center at Baylor College of Medicine, Houston, Texas 77030, USA.

    • Margaret Morgan
    •  & Richard Gibbs
  7. Dan L. Duncan Cancer Center, Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas 77030, USA.

    • Chad J. Creighton
    •  & Lawrence Donehower
  8. Baylor College of Medicine, Houston, Texas 77030, USA.

    • Carolyn Smith
  9. The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, Massachusetts 02142, USA.

    • David J. Kwiatkowski
    • , Andrew D. Cherniack
    • , Jaegil Kim
    • , Chandra Sekhar Pedamallu
    • , Michael S. Noble
    • , Carrie Sougnez
    • , Kristian Cibulskis
    • , Lee Lichtenstein
    • , Andrey Sivachenko
    • , Chip Stewart
    • , Michael S. Lawrence
    • , Gad Getz
    • , Eric Lander
    • , Stacey B. Gabriel.
    • , Scott L. Carter
    • , Gordon Saksena
    • , Steven E. Schumacher
    • , Samuel S. Freeman
    • , Joonil Jung
    • , Ami S. Bhatt
    • , Trevor Pugh
    • , Rameen Beroukhim
    • , Stacey B. Gabriel
    • , Matthew Meyerson
    • , Lynda Chin
    • , Juok Cho
    • , Daniel DiCara
    • , Scott Frazer
    • , Nils Gehlenborg
    • , David I. Heiman
    • , Pei Lin
    • , Yingchun Liu
    • , Petar Stojanov
    • , Doug Voet
    • , Hailei Zhang
    •  & Lihua Zou
  10. Brigham and Women’s Hospital, 75 Francis St, Boston, Massachusetts 02115, USA.

    • David J. Kwiatkowski
    •  & Tod D. Casasent
  11. Harvard Medical School, Boston, Massachusetts 02115, USA.

    • David J. Kwiatkowski
  12. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.

    • Chandra Sekhar Pedamallu
    • , Ami S. Bhatt
    • , Trevor Pugh
    • , Rameen Beroukhim
    • , Matthew Meyerson
    •  & Petar Stojanov
  13. Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.

    • Hikmat A. Al-Ahmadie
    • , Victor E. Reuter
    • , Jonathan E. Rosenberg
    • , Dean F. Bajorin
    • , Bernard H. Bochner
    • , David B. Solit
    • , Ilana R. Garcia-Grossman
    •  & Ashley M. Regazzi
  14. Oregon Health and Science University, Department of Urology, 3303 SW Bond Avenue, CHH10U, Portland, Oregon 97239, USA.

    • Theresa Koppie
  15. Weill Medical College of Cornell University, New York, New York 10065, USA.

    • Brian Robinson
  16. National Institute of Environmental Health Sciences, 111 T.W. Alexander Drive, Research Triangle Park, North Carolina 27709, USA.

    • Dmitry A. Gordenin
    • , David Fargo
    • , Leszek J. Klimczak
    •  & Steven A. Roberts
  17. Optimum Therapeutics LLC, 9363 Towne Centre Drive, San Diego, California 92121, USA.

    • Jessie Au
  18. University of Southern California Epigenome Center, University of Southern California, Los Angeles, California 90033, USA.

    • Peter W. Laird
    • , Toshinori Hinoue
    • , Hui Shen
    • , Moiz S. Bootwalla
    • , Timothy Triche Jr
    • , Phillip H. Lai
    • , David J. Van Den Berg
    •  & Daniel J. Weisenberger
  19. Computational Biology Center, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USA.

    • Nikolaus Schultz
    • , Ricardo Ramirez
    • , Jianjiong Gao
    • , Anders Jacobsen
    • , B. Arman Aksoy
    • , Yevgeniy Antipin
    • , Giovanni Ciriello
    • , Gideon Dresdner
    • , Benjamin Gross
    • , William Lee
    • , Boris Reva
    • , Ronglai Shen
    • , Rileen Sinha
    • , S. Onur Sumer
    • , Nils Weinhold
    • , Marc Ladanyi
    •  & Chris Sander
  20. UCSD Department of Pathology 9500 Gilman Drive, La Jolla, California 92093, USA.

    • Donna Hansel
  21. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.

    • Katherine A. Hoadley
    • , William Y. Kim
    • , Jeffrey S. Damrauer
    • , Saianand Balu
    • , Tom Bodenheimer
    • , Jeffrey S. Damrauer Alan P. Hoyle
    • , Stuart R. Jefferys
    • , Shaowu Meng
    • , Lisle E. Mose
    • , Janae V. Simons
    • , Mathew G. Soloway
    • , Junyuan Wu
    • , Joel S. Parker
    •  & D. Neil Hayes
  22. Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.

    • William Y. Kim
    • , Jeffrey S. Damrauer
    • , Jeffrey S. Damrauer Alan P. Hoyle
    • , Joel S. Parker
    • , Charles M. Perou
    •  & Matthew D. Wilkerson
  23. Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.

    • William Y. Kim
  24. Cancer Biology Division, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland 21231, USA.

    • Stephen B. Baylin
  25. Massachusetts General Hospital, Cancer Center and Department of Pathology, 55 Fruit Street, Boston, Massachusetts 02114, USA.

    • Gad Getz
  26. Department of Molecular Virology and Microbiology, Baylor College of Medicine, 1 Baylor Plaza, Houston, Texas 77030, USA.

    • Lawrence Donehower
  27. Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.

    • Steven E. Schumacher
  28. Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215, USA.

    • Rameen Beroukhim
  29. Department of Pathology, Harvard Medical School, Boston, Massachusetts 02215, USA.

    • Matthew Meyerson
  30. Canada’s Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia V5Z 4S6, Canada.

    • Andrew J. Mungall
    • , A. Gordon Robertson
    • , Andy Chu.
    • , Andy Chu
    • , Adrian Ally
    • , Miruna Balasundaram
    • , Yaron S. N. Butterfield
    • , Noreen Dhalla
    • , Carrie Hirst
    • , Robert A. Holt
    • , Steven J. M. Jones
    • , Darlene Lee
    • , Haiyan I. Li
    • , Marco A. Marra
    • , Richard A. Moore
    • , Jacqueline E. Schein
    • , Payal Sipahimalani
    • , Angela Tam
    • , Nina Thiessen
    • , Tina Wong
    • , Natasja Wye
    • , Reanne Bowlby
    • , Eric Chuah
    •  & Ranabir Guin
  31. Department of Internal Medicine, Division of Medical Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.

    • D. Neil Hayes
  32. Research Computing Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.

    • Jeffrey Roach
  33. Carolina Center for Genome Sciences, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.

    • Elizabeth Buda
    •  & Corbin D. Jones
  34. Department of Biology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.

    • Corbin D. Jones
    • , Piotr A. Mieczkowski
    • , Donghui Tan
    • , Umadevi Veluvolu
    •  & Scot Waring
  35. Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.

    • J. Todd Auman
  36. Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA.

    • Netty Santoso
    • , Michael Parfenov
    • , Xiaojia Ren
    • , Angeliki Pantazi
    • , Angela Hadjipanayis
    • , Jonathan Seidman
    •  & Raju Kucherlapati
  37. Division of Genetics, Brigham and Women’s Hospital, Boston, Massachusetts 02115, USA.

    • Angela Hadjipanayis
    • , Raju Kucherlapati
    • , Peter J. Park
    •  & Andrew Wei Xu
  38. The Center for Biomedical Informatics, Harvard Medical School, Boston, Massachusetts 02115, USA.

    • Semin Lee
    • , Lixing Yang
    •  & Peter J. Park
  39. Informatics Program, Children’s Hospital, Boston, Massachusetts 02115, USA.

    • Peter J. Park
  40. Institute for Applied Cancer Science, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

    • Alexei Protopopov
    • , Jianhua Zhang
    • , Christopher Bristow
    • , Harshad S. Mahadeshwar
    • , Sahil Seth
    • , Xingzhi Song
    • , Jiabin Tang
    • , Dong Zeng
    •  & Lynda Chin
  41. The University of Texas MD Anderson Cancer Center, Department of Pathology, Unit 085; 1515 Holcombe Boulevard, Houston, Texas 77030, USA.

    • Charles Guo
    • , Jolanta Bondaruk
    • , Bogdan Czerniak
    •  & Kenneth Aldape
  42. Institute for Systems Biology, 401 Terry Ave N, Seattle, Washington 98109, USA.

    • Brady Bernard
    • , Dick Kreisberg
    • , Sheila Reynolds
    • , Hector Rovira
    •  & Ilya Shmulevich
  43. Buck Institute for Research on Aging; 8001 Redwood Blvd, Novato, California 94945, USA.

    • Christopher Benz
  44. University California Santa Cruz, 1156 High Street, Santa Cruz, California 95064, USA.

    • Daniel Carlin
    • , David Haussler
    • , Sam Ng
    • , Evan O. Paull
    • , Joshua Stuart
    •  & Jing Zhu
  45. Department of Pathology, MD Anderson Cancer Center, Houston, Texas 77030, USA.

    • Yuexin Liu
    •  & Wei Zhang
  46. Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California 94158, USA.

    • Barry S. Taylor
  47. The Research Institute at Nationwide Children’s Hospital, Columbus, Ohio 43205, USA.

    • Tara M. Lichtenberg
    • , Erik Zmuda
    • , Thomas Barr
    • , Aaron D. Black
    • , Myra George
    • , Benjamin Hanf
    • , Carmen Helsel
    • , Cynthia McAllister
    • , Nilsa C. Ramirez
    • , Teresa R. Tabler
    • , Stephanie Weaver
    • , Lisa Wise
    • , Jay Bowen
    •  & Julie M. Gastier-Foster
  48. The Ohio State University, Columbus, Ohio 43210, USA.

    • Nilsa C. Ramirez
    •  & Julie M. Gastier-Foster
  49. Department of Pathology, Baylor College of Medicine, Houston, Texas 77030, USA.

    • Michael Ittman
    •  & Patricia Castro
  50. Analytical Biological Services, Inc., 701 Cornell Drive, Wilmington, Delaware 19801, USA.

    • Charles Saller
    •  & Katherine Tarvin
  51. Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA.

    • Jennifer M. DiPiero
    •  & Jennifer Owens
  52. Georgia Regents University Cancer Center. Augusta, Georgia 30912, USA.

    • Roni Bollag
    • , Qiang Li
    •  & Paul Weinberger
  53. Helen F. Graham Cancer Center at Christiana Care, 4701 Ogletown Stanton Road, Newark, Delaware 19713, USA.

    • Christine Czerwinski
    • , Lori Huelsenbeck-Dill
    • , Mary Iacocca
    • , Nicholas Petrelli
    • , Brenda Rabeno
    •  & Pat Swanson
  54. International Genomics Consortium, 445 N. Fifth Street, Phoenix, Arizona 85004, USA.

    • Troy Shelton
    • , Erin Curley
    • , Johanna Gardner
    • , David Mallery
    •  & Robert Penny
  55. ILSbio, LLC 100 Radcliffe Drive, Chestertown, Maryland 21620, USA.

    • Nguyen Van Bang
    • , Phan Thi Hanh
    • , Bernard Kohl
    • , Xuan Van Le
    • , Bui Duc Phu
    • , Richard Thorp
    • , Nguyen Viet Tien
    •  & Le Quang Vinh
  56. Hue Central Hospital, Hue City, Vietnam.

    • Nguyen Van Bang
    • , Phan Thi Hanh
    • , Bui Duc Phu
    • , Nguyen Viet Tien
    •  & Le Quang Vinh
  57. IU School of Medicine, Med Science Bldg, Room 128A, 635 Barnhill Drive, Indianapolis, Indiana 46202, USA.

    • George Sandusky
  58. Lahey Hospital and Medical Center, Burlington, Massachusetts 01805, USA.

    • Eric Burks
    • , Kimberly Christ
    • , Jason Gee
    • , Antonia Holway
    • , Alireza Moinzadeh
    • , Andrea Sorcini
    •  & Travis Sullivan
  59. University of North Carolina, Lineberger Cancer Center, 450 West Drive, Chapel Hill, North Carolina 27599, USA.

    • Lori Boice
    • , Wendy Kimryn Rathmell
    •  & Leigh Thorne
  60. University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA.

    • Sheldon Bastacky
    • , Benjamin Davies
    • , Rajiv Dhir
    • , Jeffrey Gingrich
    • , Ronald Hrebinko
    • , Jodi Maranchie
    • , Joel Nelson
    •  & Anil Parwani
  61. Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, New York 14063, USA.

    • Wiam Bshara
    • , Carmelo Gaudioso
    •  & Carl Morrison
  62. Ontario Tumour Bank—Hamilton site, St Joseph’s Healthcare Hamilton, Hamilton, Ontario L8N 3Z5, Canada.

    • Vina Alexopoulou
    • , John Bartlett
    • , Jay Engel
    •  & Sugy Kodeeswaran
  63. The University of Chicago, Chicago, Illinois 60637, USA.

    • Tatjana Antic
    • , Peter H. O’Donnell
    • , Norm D. Smith
    •  & Gary D. Steinberg
  64. University of Miami, Sylvester Comprehensive Cancer Center, 1550 NW 10th Avenue, Miami, Florida 33136, USA.

    • Sophie Egea
    • , Carmen Gomez-Fernandez
    • , Lynn Herbert
    • , Merce Jorda
    •  & Mark Soloway
  65. UT Southwestern Medical Center 5323 Harry Hines Blvd, Dallas, Texas 75390-9110, USA.

    • Allison Beaver
    • , Suzie Carter
    • , Payal Kapur
    • , Cheryl Lewis
    •  & Yair Lotan
  66. Stanford University, Department of Urology, 300 Pasteur Drive, Suite S287, Stanford, California 94305, USA.

    • Eila Skinner
  67. SRA International, Fairfax, Virginia 22033, USA.

    • Mark A. Jensen
    • , Ari B. Kahn
    • , Todd D. Pihl
    • , David A. Pot
    • , Deepak Srinivasan
    •  & Yunhu Wan
  68. MLF Consulting, Arlington, Massachusetts 02474, USA.

    • Martin L. Ferguson
  69. National Cancer Institute, 31 Center Drive, 3A20, Bethesda, Maryland 20892, USA.

    • Jean Claude Zenklusen
    • , Tanja Davidsen
    • , John A. Demchok
    • , Kenna R. Mills Shaw
    • , Margi Sheth
    • , Roy Tarnuzzer
    • , Zhining Wang
    •  & Liming Yang
  70. National Human Genome Research Institute, 5635 Fishers Lane, Rockville, Maryland 20852, USA.

    • Carolyn Hutter
    • , Bradley A. Ozenberger
    •  & Heidi J. Sofia
  71. Scimentis, LLC, Atlanta, Georgia 30666, USA.

    • Greg Eley


  1. The Cancer Genome Atlas Research Network

    Analysis working group: The University of Texas MD Anderson Cancer Center

    Baylor College of Medicine

    Broad Institute

    Memorial Sloan-Kettering Cancer Center

    Oregon Health and Science University, Department of Urology

    Weill Medical College of Cornell University

    National Institute of Environmental Health Sciences

    Optimum Therapeutics LLC

    University of Southern California Epigenome Center

    Computational Biology Center, Memorial Sloan-Kettering Cancer Center

    UCSD Department of Pathology

    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill

    Department of Genetics, University of North Carolina at Chapel Hill

    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University

    Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency

    Genome Sequencing Center: Broad Institute

    Genome characterization centres: Dan L. Duncan Cancer Center, Human Genome Sequencing Center, Baylor College of Medicine

    Broad Institute

    Canada’s Michael Smith Genome Sciences Centre, BC Cancer Agency

    University of Southern California Epigenome Center

    UCSD Department of Pathology

    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill

    Research Computing Center, University of North Carolina at Chapel Hill

    Carolina Center for Genome Sciences, University of North Carolina at Chapel Hill

    Department of Biology, University of North Carolina at Chapel Hill

    Eshelman School of Pharmacy, University of North Carolina at Chapel Hill

    Department of Genetics, University of North Carolina at Chapel Hill

    Department of Genetics, Harvard Medical School

    The Center for Biomedical Informatics, Harvard Medical School

    Cancer Biology Division, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University

    Division of Genetics, Brigham and Women’s Hospital

    Institute for Applied Cancer Science, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center

    The University of Texas MD Anderson Cancer Center, Department of Pathology

    Genome data analysis centres: The University of Texas M.D. Anderson Cancer Center

    Broad Institute

    Institute for Systems Biology

    Computational Biology Center, Memorial Sloan-Kettering Cancer Center

    Buck Institute for Research on Aging

    University of California Santa Cruz

    Department of Pathology, MD Anderson Cancer Center

    Helen Diller Family Comprehensive Cancer Center, University of California

    Biospecimen core resource: The Research Institute at Nationwide Children’s Hospital

    Tissue source sites: The University of Texas MD Anderson Cancer Center

    Scott Department of Urology, Baylor College of Medicine

    Texas Cancer Research Biobank (TCRB), Baylor College of Medicine

    Broad Institute

    Analytical Biological Services, Inc.

    Cleveland Clinic Foundation

    Georgia Regents University Cancer Center

    Helen F. Graham Cancer Center at Christiana Care

    International Genomics Consortium

    ILSbio, LLC

    IU School of Medicine

    Lahey Hospital and Medical Center

    Memorial Sloan-Kettering Cancer Center

    Oregon Health and Science University, Department of Urology

    University of North Carolina, Lineberger Cancer Center

    University of Pittsburgh

    Roswell Park Cancer Institute

    Ontario Tumour Bank—Hamilton site, St Joseph’s Healthcare Hamilton

    The University of Chicago

    University of Miami, Sylvester Comprehensive Cancer Center

    UT Southwestern Medical Center

    Weill Medical College of Cornell University

    UCSD Department of Pathology

    The University of Texas MD Anderson Cancer Center, Department of Pathology

    Disease working group: The University of Texas MD Anderson Cancer Center

    Scott Department of Urology, Baylor College of Medicine

    Baylor College of Medicine

    Broad Institute

    Memorial Sloan-Kettering Cancer Center

    Oregon Health and Science University, Department of Urology

    Weill Medical College of Cornell University

    Stanford University, Department of Urology

    Computational Biology Center, Memorial Sloan-Kettering Cancer Center

    UCSD Department of Pathology

    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill

    The University of Texas MD Anderson Cancer Center, Department of Pathology

    Data coordination centre: SRA International

    Project team: MLF Consulting

    National Cancer Institute

    National Human Genome Research Institute

    Scimentis, LLC



    The Cancer Genome Atlas research network contributed collectively to this study. Biospecimens were provided by the tissue source sites and processed by the Biospecimen Core Resource. Data generation and analyses were performed by the genome-sequencing centres, cancer genome-characterization centres and genome data analysis centres. All data were released through the Data Coordinating Center. Project activities were coordinated by the NCI and NHGRI project teams. We also acknowledge the following TCGA investigators of the Bladder Analysis Working Group who contributed substantially to the project. Project leaders: J. N. Weinstein and S. P. Lerner. Data coordinator: C. J. Creighton. Analysis coordinators: R. Akbani and J. Kim. Manuscript coordinator: M. B. Morgan. Project coordinator: M. Sheth. Writing team: J. N. Weinstein, D. J. Kwiatkowski, S. P. Lerner, C. J. Creighton, P. W. Laird, R. Kucherlapati, R. Akbani, X. Su, K. A. Hoadley and M. C. Ryan. Clinical expertise: S. Lerner, D. J. Kwiatkowski, J. E. Rosenberg and D. Bajorin. Pathology review: H. Al-Ahmadie, B. A. Czerniak, D. Hansel, V. Reuter and B. Robinson. DNA sequence and copy number analysis: J. Kim, D. J. Kwiatkowski, A. D. Cherniack and J. E. Rosenberg. DNA methylation analysis: P. W. Laird and T. Hinoue. mRNA analysis: K. A. Hoadley, W. Y. Kim, J. S. Damrauer, W. Zhang, Y. Liu and R. Akbani. miRNA analysis: G. Robertson and A. J. Mungall. Transcript splicing analysis: M. Ryan and J. N. Weinstein. Protein analysis: R. Akbani and G. B. Mills. APOBEC: D. A. Gordenin. Pathway/integrated analysis: C. J. Creighton, N. Schultz, Evan O. Paull and J. Stuart. Chromosomal rearrangements and viral integration: X. Su, R. Kucherlapati, N. Santoso, S. Lee and M. Parfenov. Batch effects: R. Akbani and J. N. Weinstein. Manuscript review: R. Gibbs, C. Gunter and M. Meyerson. Contact PIs: J. N. Weinstein, S. P. Lerner and D. J. Kwiatkowski.

    Competing interests

    The author declare no competing financial interests.

    Corresponding authors

    Correspondence to John N. Weinstein or Seth Lerner or David J. Kwiatkowski or David J. Kwiatkowski or John N. Weinstein or John N. Weinstein or Seth Lerner or John N. Weinstein or Seth Lerner or David J. Kwiatkowski.

    The primary and processed data used to generate the analyses presented here can be downloaded by registered users from The Cancer Genome Atlas at All of the primary sequence files are deposited in CGHub and all other data are deposited at the Data Coordinating Center (DCC) for public access (, and

    Supplementary information

    PDF files

    1. 1.

      Supplementary Information

      This file contains Supplementary Text and Data, Supplementary Figures, Supplementary Tables and additional references – see Contents for details.

    About this article

    Publication history





    Further reading


    By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.